Amylyx Pharmaceuticals Inc.   Report issue

For profit Phase 2 Phase 3
Founded: Cambridge MA United States (2013)

Organization Overview

First Clinical Trial
2017
NCT03127514
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Amylyx Pharmaceuticals Inc.

Active Ingredients

Drugs in Phase 3 Trials (2)

sodium phenylbutyrate (buphenyl) (7 trials)

taurursodiol (Relyvrio) (6 trials)

Drugs in Phase 2 Trials (1)

ursodeoxycholyltaurine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Amyotrophic Lateral Sclerosis (Phase 3)

Central Nervous System Diseases (Phase 2)

Motor Neuron Disease (Phase 3)

Nervous System Diseases (Phase 2)

Neurodegenerative Diseases (Phase 2)

Neuromuscular Diseases (Phase 2)

Sclerosis (Phase 3)

Spinal Cord Diseases (Phase 2)

TDP-43 Proteinopathies (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 3